NCT05630963Recruiting
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
Source: ClinicalTrials.gov · Last updated 21 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 228 (estimated)
- First submitted
- 16 Nov 2022
- Start date
- 29 Dec 2021
- Primary completion date
- 28 Oct 2026
- Lead sponsor
- Mclean Hospital
- Diseases
- Depression
- NCT number
- NCT05630963
What you commit to
- Study type: Observational
- Planned participants: 228
- From 29 Dec 2021 to the primary completion date, 28 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, IUD, s/p tubal ligation, or partner with vasectomy)
- Current use of other psychotropic drugs
Other illness
- Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease
- History of seizure disorder
- History of psychiatric illnesses, other than depression or anxiety disorders among the Current MDD and Remitted MDD groups
- History of substance use disorder or alcohol use disorder (as these terms are defined by DSM-5); except depressed subjects may have a history of 'Mild' substance/alcohol use disorder only if it ended as least 12 months ago
- History of cocaine or stimulant use or dopaminergic drugs
- History or current diagnosis of dementia, or a score of \< 26 on the Mini Mental State Examination at the screening visit;
- Patients with a lifetime history of electroconvulsive therapy (ECT)
- Failure to meet standard MRI safety requirements
- History of seizure disorder
- Contraindications for arterial line (e.g., abnormal result on Allen test, Raynaud's syndrome, history of anemia or bleeding disorder, history of fainting from blood draws).
Lab values
- Clinical or laboratory evidence of hypothyroidism
Other
- Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician. These patients will be immediately referred to appropriate clinical treatment
- Patients with mood congruent or mood incongruent psychotic features
- Abnormal ECG and lab results
Who the study is looking for
- All genders, races, and ethnic origins, aged between 18 and 45
- Capable of providing written informed consent, and fluent in English
- Right-handed
- Absence of any psychotropic medications for at least 2 weeks
- Has a smartphone (iPhone or Android) (needed for Ecological Momentary Assessment)
- Meets inclusion criteria for all subjects, plus:
- History of MDD as defined by DSM-5
- Absence of anxiety disorder for the past two months
- Meets inclusion criteria for all subjects, plus:
- Presence of MDD as defined by DSM-5
- Absence of anxiety disorder for the past two months
Age in the registry: 18 years to 45 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McLean Hospital Coordinator of this site? Confirm its status | Belmont | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.